-

Moderna to Present at Upcoming Investor Conferences in September 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

  • Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:00 a.m. ET
  • Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:45 a.m. ET

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 23 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

Moderna, Inc.

NASDAQ:MRNA

Release Summary
Moderna to present at upcoming investor conferences in September 2021.
Release Versions

Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

More News From Moderna, Inc.

Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant...

Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

CAMRIDGE, Mass.--(BUSINESS WIRE)--Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia...

Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022...
Back to Newsroom